

**REMARKS**


Claims 1-9, 11-13, 15-18, 20-23, 27 and 29 are pending in the application.

Claims 11 and 12 have been rejected under 35 USC 112, first paragraph, by the Examiner as being vague and indefinite in that they are dependent upon a cancelled claim. The claims have been amended to depend from a pending claim, rendering this rejection of the claims moot.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

  
Bonnie L. Deppenbrock  
Attorney for Applicant  
Registration No. 28,209

Date: May 7, 2009  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-1577  
Facsimile: 919-483-7988